Product Description
For Advanced Solid Tumors (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00792558)
Mechanisms of Action: C-Met Inhibitor, AXL Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer|Squamous Cell Carcinoma|Papillary Carcinoma|Esophageal Cancer|Renal Cell Carcinoma|Head and Neck Cancer|Gastrointestinal Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ASLAN002-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2016-12-01 |
2023-04-15 |
Primary Endpoints|Treatments |
|
| CA195-001 | P1 |
Withdrawn |
Oncology Solid Tumor Unspecified |
2010-11-01 |
2019-03-18 |
||
| CA192-002 | P2 |
Completed |
Squamous Cell Carcinoma|Esophageal Cancer|Renal Cell Carcinoma|Papillary Carcinoma|Head and Neck Cancer|Prostate Cancer|Gastrointestinal Cancer |
2009-03-01 |
2019-03-18 |
Treatments |